Interleukin 31 in insect bite hypersensitivity-Alleviating clinical symptoms by active vaccination against itch.
allergic pruritus
interleukin 31
vaccination
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
21
06
2019
revised:
15
08
2019
accepted:
02
09
2019
pubmed:
10
12
2019
medline:
11
5
2021
entrez:
10
12
2019
Statut:
ppublish
Résumé
Insect bite hypersensitivity (IBH) is the most common seasonal pruritic allergic dermatitis of horses occurring upon insect bites. In recent years, a major role for IL-31 in allergic pruritus of humans, monkeys, dogs, and mice was acknowledged. Here, we investigate the role of IL-31 in IBH of horses and developed a therapeutic vaccine against equine IL-31 (eIL-31). IL-31 levels were quantified in allergen-stimulated peripheral blood mononuclear cells (PBMCs) and skin punch biopsies of IBH lesions and healthy skin from IBH-affected and healthy horses. The vaccine consisted of eIL-31 covalently coupled to a virus-like particle (VLP) derived from cucumber mosaic virus containing a tetanus toxoid universal T-cell epitope (CuMVTT). Eighteen IBH-affected horses were recruited and immunized with 300 μg of eIL-31-CuMVTT vaccine or placebo and IBH severity score was recorded. IL-31 was increased in PBMCs and exclusively detectable in skin lesions of IBH-affected horses. Vaccination against eIL-31 reduced delta clinical scores when compared to previous untreated IBH season of the same horses and to placebo-treated horses in the same year. The vaccine was well tolerated without safety concerns throughout the study. TH2-derived IL-31 is involved in IBH pathology and accordingly the immunotherapeutic vaccination approach targeting IL-31 alleviated clinical scores in affected horses.
Sections du résumé
BACKGROUND
Insect bite hypersensitivity (IBH) is the most common seasonal pruritic allergic dermatitis of horses occurring upon insect bites. In recent years, a major role for IL-31 in allergic pruritus of humans, monkeys, dogs, and mice was acknowledged. Here, we investigate the role of IL-31 in IBH of horses and developed a therapeutic vaccine against equine IL-31 (eIL-31).
METHODS
IL-31 levels were quantified in allergen-stimulated peripheral blood mononuclear cells (PBMCs) and skin punch biopsies of IBH lesions and healthy skin from IBH-affected and healthy horses. The vaccine consisted of eIL-31 covalently coupled to a virus-like particle (VLP) derived from cucumber mosaic virus containing a tetanus toxoid universal T-cell epitope (CuMVTT). Eighteen IBH-affected horses were recruited and immunized with 300 μg of eIL-31-CuMVTT vaccine or placebo and IBH severity score was recorded.
RESULTS
IL-31 was increased in PBMCs and exclusively detectable in skin lesions of IBH-affected horses. Vaccination against eIL-31 reduced delta clinical scores when compared to previous untreated IBH season of the same horses and to placebo-treated horses in the same year. The vaccine was well tolerated without safety concerns throughout the study.
CONCLUSION
TH2-derived IL-31 is involved in IBH pathology and accordingly the immunotherapeutic vaccination approach targeting IL-31 alleviated clinical scores in affected horses.
Identifiants
pubmed: 31816097
doi: 10.1111/all.14145
pmc: PMC7217000
doi:
Substances chimiques
Interleukins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
862-871Informations de copyright
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Nat Immunol. 2004 Jul;5(7):752-60
pubmed: 15184896
J Allergy Clin Immunol. 2018 Mar;141(3):858-866
pubmed: 29366565
J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6
pubmed: 27717666
BMC Biotechnol. 2006 Apr 27;6:24
pubmed: 16643647
Med Vet Entomol. 1990 Oct;4(4):375-81
pubmed: 2133005
Vet Rec. 2002 Dec 7;151(23):691-3
pubmed: 12503787
Allergy. 2020 Apr;75(4):862-871
pubmed: 31816097
Vet Dermatol. 2016 Feb;27(1):34-e10
pubmed: 26666963
Equine Vet J. 1983 Jul;15(3):266-72
pubmed: 6884318
J Allergy Clin Immunol. 2014 Feb;133(2):448-60
pubmed: 24373353
J Invest Dermatol. 2018 Jun;138(6):1311-1317
pubmed: 29317264
Vet Immunol Immunopathol. 2012 Jun 30;147(3-4):113-26
pubmed: 22575371
Rheumatol Int. 2016 Jun;36(6):799-805
pubmed: 26769434
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):142-150
pubmed: 27501029
Allergy. 2011 Jul;66(7):845-52
pubmed: 21261663
Mol Biol Rep. 2013 Apr;40(4):3333-40
pubmed: 23275235
J Allergy Clin Immunol. 2018 Oct;142(4):1194-1205.e3
pubmed: 29627082
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Feb 28;43(2):124-130
pubmed: 29559593
Vet Immunol Immunopathol. 2009 Sep 15;131(1-2):140-3
pubmed: 19409622
Vet Dermatol. 2019 Jan 23;:
pubmed: 30672050
Postepy Dermatol Alergol. 2013 Oct;30(5):282-5
pubmed: 24353487
J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S486-94
pubmed: 12592295
Vet Immunol Immunopathol. 2012 Mar 15;146(1):46-52
pubmed: 22341524
Vet Rec. 1983 May 28;112(22):521-4
pubmed: 6879963
J Allergy Clin Immunol. 2006 Feb;117(2):411-7
pubmed: 16461142
Vet Immunol Immunopathol. 2013 Apr 15;152(3-4):260-8
pubmed: 23351640
N Engl J Med. 2017 Mar 2;376(9):826-835
pubmed: 28249150
J Med Entomol. 1991 Sep;28(5):685-93
pubmed: 1941937
Allergy. 2019 Mar;74(3):572-582
pubmed: 30402930
Nature. 1993 May 13;363(6425):172-6
pubmed: 8483502
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):347-56
pubmed: 18926762
Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):283-98
pubmed: 11044560
Equine Vet J. 1999 Nov;31(6):466-72
pubmed: 10596926
Vet J. 2011 Mar;187(3):347-51
pubmed: 20097587
Equine Vet J. 1990 Jul;22(4):236-40
pubmed: 1976506
J Immunol. 2004 Feb 15;172(4):2225-31
pubmed: 14764690
Equine Vet J. 1978 Oct;10(4):243-8
pubmed: 738265
Allergy. 2010 Jun 1;65(6):712-21
pubmed: 19889120
J Comp Pathol. 1994 Feb;110(2):145-52
pubmed: 8040382
Gastroenterol Hepatol (N Y). 2012 Feb;8(2):131-4
pubmed: 22485082
Vet J. 2013 Oct;198(1):141-7
pubmed: 23891138